Targeted Alpha Therapies
​​​Targeted Alpha Therapies (TATs) are emerging as a highly-promising approach to cancer treatment, harnessing the unique properties of alpha particles to deliver extremely-potent alpha radiation directly to cancer cells (a single alpha particle can be enough to kill a cancer cell vs. hundreds of hits needed from a beta particle) while sparing surrounding healthy tissue thanks to their short, focused range (50 to 100 micrometers - 2-3 cell diameters - vs. several mm for betas).​​
​​This combination of properties, enhanced by the addition of a targeting vector to guide the alpha-emitting radionuclides towards their targets, makes TATs particularly well-suited to improve clinical outcomes for patients at risk of metastases & residual disease.
Astatine-211 (²¹¹At)
​​Astatine-211 (²¹¹At) is an alpha-emitting radionuclide considered by many to be a "goldilocks emitter" poised to lead the next-generation of targeted alpha therapies due to its unique properties.
Astatine-211 offers several distinct advantages over other alpha emitters like Actinium-225 (225Ac) and Bismuth-213 (213Bi) including:​​​​
-
​​A Short Half-life (7.2h), Minimizing Unwanted Exposure to Radiation
-
A Short & Clean Decay Chain, Minimizing Off-Target Toxicity
-
Chelatorless Chemistry, Simplifying Drug Design
-
Production from Naturally-Abundant Bismuth-209, Enabling Reliable & Cost-Effective Decentralized Manufacturing​​​​​​​​​​​​​​​
NY-703
NY-703 is a GPC3-targeting astatine-211 alpha therapy for the treatment of residual disease & metastasis in hepatocellular carcinoma (HCC).
It consists of:​​​​​​​​​
NY-703 is planning for accelerated development and aiming for initial clinical data in 2026. ​​​​​​​​
Unlocking Access With a Decentralized Astatine-211 Supply Network
Despite its highly-promising therapeutic properties, astatine-211's
use has until now been restricted to a limited number of specialized academic centers due its rare natural occurrence and short-half life making in challenging to establish an efficient, reliable global supply chain. A decentralized, hub & spoke supply chain - enabled by recent technological breakthroughs & innovations - shows promise to overcomes this hurdle. ​
NAYA is joining these efforts as an early-mover, quickly establishing partnerships with both astatine-211 & drug manufacturing sites in major metropolitan areas across the US, Europe, and Asia to unlock and ensure reliable patient access to ²¹¹At therapies.
Read more about our Ionetix, Atley, and Alpha Nuclide partnerships.
​
Learn more about the potential of astatine-211 targeted alpha therapies through highlights from our recent webinar with industry leaders & clinical experts.